You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Go to Top Close

Clinical evidence1,2

Between 10 and 20% of the inhaled Ventolin dose reaches the lower airways.1 Absorption into pulmonary tissues allows Ventolin to act directly on the lung to provide rapid, effective, and well-tolerated bronchodilatory effect.1,2

Pharmacokinetic (PK) profile of Ventolin1,2

Inhaled Ventolin has a fast onset of action and peak effect.1-2 Key Ventolin PK characteristics:1

  • After administration by the inhaled route, between 10 and 20% of the dose reaches the lower airways.1
  • Absorbed into the pulmonary tissue and circulation, but not metabolised by the lungs
  • Minimal plasma protein binding (10%)
  • Excreted in the urine after hepatic metabolism
  • 4-6 hour half-life

Efficacy of Ventolin2

Highly effective relief of bronchospasm2

Ventolin is the most widely prescribed bronchodilator for the acute treatment of asthma.3

Ventolin provides peak bronchodilation within 10 minutes with a duration of effect up to 6 hours.2 The efficacy of Ventolin has been confirmed in numerous clinical trials.2

Adults and children with asthma:2

  • Ventolin, 200 μg, significantly improved (p <.05) both FEV1 and peak expiratory flow (PEF) compared with terbutaline, 500 μg, with a trend towards greater bronchodilation with Ventolin.

For exercise-induced asthma:1,2

  • Inhaled Ventolin is extremely effective for prophylaxis of exercise- induced asthma.1,2 A single Ventolin inhalation (200 mcg) provides superior protection against abnormal pulmonary response to exercise as compared to sodium cromoglycate, theophylline and inhaled ipratropium bromide

For severe acute asthma:2

  • Nebulised Ventolin is established standard therapy in severe acute asthma. Comparative clinical trials in severe acute asthma have demonstrated Ventolin to be more effective than epinephrine, aminophylline or sodium cromoglycate, and as effective as terbutaline and ipratropium.

Safety profile of Ventolin1-2

Well-tolerated relief of bronchospasm2

The tolerability of Ventolin has been demonstrated in 20 years of clinical use.2Ventolin is a well-tolerated therapy for most patients suffering from reversible obstructive airways diseases.2Adverse effects are generally infrequent.2 The most common adverse effects are tremor, headache, and tachycardia.1

References:

  1. Global Datasheet: Salbutamol (inhaled formulations), Version 25. 14 April 2014.
  2. Price AH, Clissold SP. Salbutamol in the 1980s. A reappraisal of its clinical efficacy. Drugs. 1989; 38(I):77-122.
  3. Page C and Humphrey P. Sir David Jack: an extraordinary drug discoverer and developer. Br J Clin Pharmacol 2012.75;5:1213–18.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Ventolin is a registered trademark of the GSK group of companies.